Prestige Biopharma announced today its participation with CancerX, a public-private partnership launched by The White House to accelerate the fight against cancer, as part of the renewed Cancer Moonshot Project. CancerX, a collaborative effort between Moffitt Cancer Center and Digital Medicine Society (DiMe), aims to unite diverse stakeholders and revolutionize cancer research, diagnosis, and treatment.
Recognizing Prestige Biopharma’s strategic approach to pancreatic cancer treatment, CancerX has invited Prestige Biopharma to share its extensive experience in this field with leading global organizations participating in the Cancer Moonshot Project.
Prestige Biopharma is committed to leveraging its participation in CancerX to actively lead various research initiatives, utilizing its unique target protein PAUF as a biomarker, in order to pioneer pancreatic cancer diagnosis, treatment, and even prevention.
One of the primary goals that Prestige Biopharma is particularly enthusiastic about is the rapid commercialization of the world’s first diagnostic kit for early detection of pancreatic cancer. Joining the Cancer Moonshot Project will boost its acceleration of the diagnostic kit.
Notable members of this project include global companies and research institutions such as Johnson & Johnson, Genentech, AstraZeneca, NCI, AWS, and Intel. The collaborative efforts of these renowned entities will serve as a powerful catalyst for emphasizing the importance of early pancreatic cancer diagnosis.
About Prestige Biopharma:
Prestige Biopharma is a Singapore-based pharmaceutical company, established in 2015. In 2021, the company was listed on the KOSPI market in Korea, showcasing its two novel antibody drugs and biosimilars of three blockbuster drugs. Notably, Prestige Biopharma is currently in the process of developing an antibody drug named PBP1510, which specifically targets and neutralizes PAUF, a protein found to be overexpressed in over 80% of pancreatic cancer patients. This protein is believed to play a crucial role in the progression and metastasis of pancreatic cancer. PBP1510 has been designated as an orphan drug by the FDA, EMA, and MFDS in 2021. It is currently undergoing Phase 1/2a clinical trials in the US and Europe and has recently been granted FDA Fast Track designation.